Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.58 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | STAT6 | P42226 | 5/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP4 | P49662 | 1/20 | 0.32 |
| ▸ | CASP5 | P51878 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | CASP9 | P55211 | 1/20 | 0.32 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.32 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58037 | 1.00 | TUBB1 (0.58) | TUBB1ELANESTAT6CYP3A4CYP2D6 | |
| SCHEMBL4378540 | 1.00 | TUBB1 (0.58) | TUBB1ELANESTAT6CYP3A4CYP2D6 | |
| SCHEMBL14592398 | 0.98 | TUBB1 (0.59) | TUBB1ELANESTAT6CYP3A4CYP2D6 | |
| SCHEMBL18421084 | 0.98 | TUBB1 (0.59) | TUBB1ELANESTAT6CYP3A4CYP2D6 | |
| SCHEMBL16316203 | 0.98 | TUBB1 (0.59) | TUBB1ELANESTAT6CYP3A4CYP2D6 | |
| SCHEMBL58832 | 0.98 | TUBB1 (0.59) | TUBB1ELANESTAT6CYP3A4CYP2D6 | |
| SCHEMBL13681898 | 0.98 | TUBB1 (0.59) | TUBB1ELANESTAT6CYP3A4CYP2D6 | |
| SCHEMBL89591 | 0.98 | TUBB1 (0.59) | TUBB1ELANESTAT6CYP3A4CYP2D6 | |
| SCHEMBL18421085 | 0.98 | TUBB1 (0.59) | TUBB1ELANESTAT6CYP3A4CYP2D6 | |
| SCHEMBL13681981 | 0.98 | TUBB1 (0.59) | TUBB1ELANESTAT6CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885ELANE 4023/4885STAT6 4739/4885 |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | DHCR7, HSD17B7, HCCS | TUBB1 1668/4885ELANE 4153/4885STAT6 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.